Meeting Homepage
Registrants Only Area
Speaker Bios
Meeting Committee
Welcome
Registration:
Registration Info
Register
Hotel Reservations
Meeting Program:
Schedule-at-a-Glance
Add-on Seminars
Plenary Sessions
Mini-Plenary Sessions
Workshops-at-a-Glance
Workshops by Track
Workshops
PDS Workshops
CLE
Leadership Forum
Additional Events:
Networking Events
Tech Fair
Tours and Sports
Accompanying Persons Schedule
Power Networking [PDF]
Sponsorship Opportunities
Tech Fair:
Exhibitor Information
Floor Plan [PDF]
Space Application [PDF]
Poster Application [PDF]
Misc. Info:
Weather and Dress
Transportation
Discount Disney Tickets Speakers Only:
Information
|
Workshops-at-a-Glance
Monday, October 20
Session 1
Session 2
Tuesday, October 21
Session 3
Session 4
Wednesday, October 22
Session 5
Session 6
Monday,
October 20
2:00 - 3:15 p.m.
Session 1
1-CEM-1: Perspectives, Issues and Options for Dealing with Patent Litigation
1-HEA-1: Performing Great Music in Pharma Corporate Development
1-HEA-3: Negotiating for Alliance Success
1-HEA-4: Strategic Bio-Pharma Deal Making: Has Alternative Financing Come of Age?
1-HTS-1: Should We Sell,
License or Spin Off?
1-HTS-2: Issues In Open Source Licensing Implications of GPLVersion 3
1-HTS-3: Best Practices: Alliances in the Semiconductor Industry
1-HTS-4: Global IP Transactions Case Studies
1-IUGI-1: Evaluating and Valuing Inventions: What is the Difference?
1-IUGI-2: The Patent Reform Storm: Lessons Learned One Year Later
1-LGL-1: Top 10 Court Decisions of 2008 Affecting Licensing
1-BMD-1: Securing Patent Protection in the Biomedical Device Field - Best Practices
1-VAL-1: Licensing in the Presence of Technological Standards
1-STR-1: Private Equity Firms: Friends or Foes?
Monday,
October 20
3:45 - 5:00 p.m.
Session 2
2-CP-1: Cargill's Successful Customer Partnership Efforts
2-HEA-5: The Art of Keeping it Together: Problem Solving during Organon's Asset Acquisition of Kadmus Pharma
2-HEA-6: Non-verbal Communication during Negotiations - What Might I Be Missing or Telegraphing?
2-HEA-7: All these Deal Tools and Comparables, but All We Need is a Napkin!
2-HEA-8: Route-Splitting, Not Indication-Splitting: A Superior Partnering Strategy to Maximize Your Molecule
2-HTS-5: Hot Topics in Licensing Digital Content in the Sports & Entertainment Industries
2-HTS-6: The Intellectual Property Growth Cycle of Early-Stage Companies
2-HTS-7: Best Practices in Licensing: Intellectual Property Policy
2-IUGI-3: Tools and Solutions for Successful Licensing Arrangements between Universities and Industry
2-IUGI-4: Adding Value to Technology through Proactive OTT Business Development
2-LGL-2: Corporate Tourniquets: The Need and Reasonableness of Obligation to Mitigate in IP Disputes
2-LGL-3: Licensing after Quanta v. LG
2-BMD-2: Creative Deals - Model Agreements for University/ Industry Collaboration in the Biomedical Device Field
2-VAL-2: Something's Wrong - Valuation, Licensing and Jury Awards in the Application Software Industry
2-STR-2: Alliances and Partnerships as an Alternative to Licensing
2-LOSM-1: Marketing Inventions: Leveraging Resouces in a Small Office
Tuesday,
October 21
2:00 - 3:15 p.m.
Session 3
3-CEM-2: Licensing and Partnering Strategy for the Emerging Biofuels Industry
3-HEA-9: The Interface, or Lack Thereof, between Corporate Venture Capital and Corporate Business Development
3-HEA-10: Acquisition Driven Business Growth
3-HEA-11: BIG versus Small: What Can Be Learned from Switching Sides
3-HEA-12: Choosing Where to Focus: How to Identify and Prioritize the Right Therapeutic Areas of Opportunity
3-HTS-8: From Amazon to Watermarking: The Year'
s Most Important Developments in DRM and Their Implications
3-HTS-9: Patent Quality and Subsequent Valuations
3-IUGI-5: Development Collaboration and License/Option Agreements: A Case from Sustainable Energy Technology Development
3-IUGI-6: Key Issues in Sublicensing
3-LGL-4: Antirust Aspects
of Patent Licensing - Recent
Developments
3-LGL-5: The Nitty-Gritty of Working Strategies in Globalized Patent Litigation
3-BMD-3: Commercialization and Growth by Acquisition in the Biomedical Device Industry, Part 1
3-VAL-3: Patent Rating Systems: What are They, Really? Part 1
3-VAL-4: Royalty Monetization
3-LOSM-2: Going Beyond Search: Correlating Multiple Data Sources for Licensing Analysis
Tuesday,
October 21
3:45 - 5:00 p.m.
Session
4
4-CP-2: Organizational Models for Brand and Technology Licensing
4-HEA-13: M&A Amongst Smaller Companies
4-HEA-14: What Buyers Want: Understanding What Big Pharma In-Licensors Expect to See in Out-Licensing Documents
4-HEA-15: Getting a Deal Done with J&J: What You Need to Know
4-HEA-16: Negotiating the Floor: Connecting through "Push-Pull" in Partnership Negotiations
4-HTS-10: Source Code Escrow: Optimal Value and Minimal Pain
4-HTS-11: Global Technology Licensing: Protecting IP Value in a Converging, Digital,
Wireless World
4-IUGI-7: Successful Ventures with the Federal Technology Process
4-IUGI-8: IP Ownership in Industry Collaborations
4-INTL-1: What Type of Clauses Should You Be Careful of in a Licensing Agreement: Review of the Law and Practice
4-LGL-6: Biotechnology Licensing Issues In View of MedImmune, Quanta Computer, and Merck KGaA
4-LGL-7: Managing the Gladiators - Surviving Patent Litigation
4-BMD-4: Commercialization and Growth by Acquisition in the Biomedical Device Industry, Part 2
4-VAL-5: Patent Rating Systems: What are They, Really? Part 2
4-CLP-1: Certified Licensing Professional and You: Q&A Workshop
4-OTH-1: Licensing Patents after "Patent Reform"
Wednesday, October 22
2:00 - 3:15 p.m.
Session 5
5-CEM-3: Trade Secret Best Practices
5-CP-3: Top Ten Black Holes in Brand Licensing
5-HEA-17: Building Franchises through Licensing and M&A
5-HEA-18: Licensing Assets to Repurpose in New Indications
5-HEA-19: Business Development under Pressure - Getting it Done, Right, Fast!
5-HEA-2: Deal or No Deal?: How to Take the Right Risks to Get the Greatest Rewards in Biotech Dealmaking
5-HTS-12: You Want to License? To THEM???
5-HTS-13: Dissolving the Myths of Licensing Outside the U.S. and Europe
5-IUGI-9: Large Company- Small Company Collaborations: Overcoming Commitment Issues
5-IUGI-10: Non-US Patent Protection: Factors in Decision Making
5-INTL-2: Rules and Pitfalls of Access to Natural Genetic Resources in Latin America
5-INTL-3: Public Health and Compulsory Licensing Issues: Global Issues
5-LGL-8: Effective Selection, Preparation, and Use of Expert Witnesses in High Technology Patent Litigation
5-LGL-9: The Legal Framework for Federal Patent Licensing
5-BMD-5: A Global Approach to Licensing Strategy and Valuation for Devices
5-CLP-2: Certified Licensing Professional and You: Q&A Workshop
5-VAL-6: Revenue Interest Financing
Wednesday, October 22
3:45 - 5:00 p.m.
Session 6
6-CP-4: Sustaining Continuous Innovation through External Partners – Case Studies by P&G and Church & Dwight
6-HEA-20: Anatomy of an Agreement: Ts & Cs and Term Sheets and all that Boilerplate
6-HEA-21: Biomarker Dealmaking
6-HEA-22: "Mining the Mine" - LES Royalty Rate Survey: Deal Terms and Valuation Metrics! - New
6-HTS-14: Case Study: IP Licensing and Technology Investments at Microsoft and GE
6-HTS-15: Towards IP Liquidity: Progress on E-Markets
6-INTL-4: The Privacy Rights Challenge Facing the Copyright/IP Rights Licensor
6-INTL-5: Global Research Collaboration: Strategies, Issues and Examples in the Americas and Nordic Countries
6-BMD-6: Navigating the
Litigation Minefield in the
Biomedical Device Industry |
